Peptides vs steroids is not a comparison between two names for the same thing. Peptides are short chains of amino acids that act as signals; anabolic steroids are testosterone-related molecules that activate the androgen receptor. Sermorelin and CJC-1295/ipamorelin work upstream of growth hormone, while BPC-157 is a separate peptide with a different research story. That distinction changes what each compound can reasonably be expected to do, its side effects, its federal legal status, and how sports regulators treat it.
Peptides vs steroids at a glance
“Peptide” describes a molecular structure, not one effect. GLP-1 medicines are peptides. So are growth-hormone-releasing compounds and many natural hormones. Their receptors and clinical purposes differ widely.
“Anabolic steroid” describes a testosterone-related class. These drugs enter cells, bind androgen receptors, and change gene transcription in tissues including muscle. Their androgenic and muscle-building effects come from that shared pathway.
| Question | Peptide medicines | Anabolic steroids |
|---|---|---|
| What are they? | Amino-acid chains | Testosterone-related steroid molecules |
| Main target | Depends on the peptide and its receptor | Androgen receptor |
| Muscle effect | Not a class-wide effect | Direct anabolic-androgenic signaling |
| Federal schedule | Not scheduled as one class | Schedule III |
| Sports rules | Some classes and named peptides are prohibited | Anabolic agents are prohibited |
The useful comparison is therefore compound against compound, not label against label. Are peptides safe? explains why one safety verdict cannot cover the whole category.
The mechanisms start in different places
Sermorelin is a 29-amino-acid analogue of growth-hormone-releasing hormone. It prompts the pituitary to release the body’s own growth hormone; it is not growth hormone or testosterone. A published review of sermorelin describes that pituitary action directly. CJC-1295 also acts on the GHRH pathway, while ipamorelin activates the ghrelin receptor. Both routes can increase growth-hormone pulses and downstream IGF-1 signaling.
That upstream action matters. The pituitary and feedback from IGF-1 remain part of the loop. An anabolic steroid instead supplies an outside androgen signal at the androgen receptor. Sermorelin versus HGH covers the separate distinction between stimulating endogenous release and administering growth hormone itself.
The muscle and strength evidence is not equivalent
The clearest steroid comparison comes from Bhasin and colleagues in the New England Journal of Medicine in 1996. Forty-three healthy men were assigned to four groups for 10 weeks. The testosterone-plus-exercise group gained 6.1 kg of fat-free mass and increased bench-press strength by 22 kg and squat capacity by 38 kg. Those results came from 600 mg of testosterone enanthate weekly—a supraphysiologic exposure—not ordinary testosterone replacement (Bhasin et al., 1996).
The growth-hormone evidence looks different. Liu and colleagues reviewed 27 study samples involving 303 healthy, physically fit participants. Growth hormone increased lean body mass by 2.1 kg on average, but strength and exercise capacity did not appear to improve (Annals of Internal Medicine, 2008). Lean mass can include water, so it should not be read automatically as new contractile muscle.
A year-long randomized trial gives a closer secretagogue reference. Among 65 healthy adults aged 60 to 81, the ghrelin mimetic MK-677 increased fat-free mass by 1.1 kg while placebo declined by 0.5 kg, yet strength and function did not change. Fasting glucose rose by an average of 5 mg/dL and insulin sensitivity decreased (Nass et al., Annals of Internal Medicine, 2008). MK-677 is not sermorelin, CJC-1295, or ipamorelin; it shows why a pathway signal or body-composition change cannot be converted into a strength claim.
Human trials have not established that compounded sermorelin or CJC-1295/ipamorelin builds strength in healthy trained adults. The best HGH peptides comparison keeps the evidence for each growth-hormone pathway separate.
The side-effect profiles are also different
Anabolic-steroid exposure can suppress the hypothalamic-pituitary-gonadal axis, reducing natural testosterone production and sperm production. Other risks vary by agent, route, dose, and duration. They include acne and hair changes, raised hematocrit, adverse lipid changes, cardiovascular injury, and liver toxicity with some oral agents. A peer-reviewed review links high-dose misuse with thrombosis, cardiomyopathy, stroke, and liver injury (Nieschlag and Vorona, 2015).
Growth-hormone-pathway compounds carry a different set of questions: fluid retention, injection-site reactions, joint or muscle discomfort, changes in appetite, and impaired glucose regulation. Risk is product-specific. The much thinner clinical record for many compounded peptides also means that “fewer reported effects” may reflect fewer and smaller human studies, not lower risk.
Legal status and sports status answer different questions
As of August 2026, the DEA’s current controlled-substances list places anabolic steroids in Schedule III. Sermorelin, CJC-1295, ipamorelin, and BPC-157 do not appear by name in that Orange Book, but DEA cautions that its lists are not comprehensive.
Sports rules use a different test. The 2026 World Anti-Doping Agency list prohibits anabolic agents and separately names GHRH analogues including sermorelin and CJC-1295, plus growth-hormone secretagogues including ipamorelin. It does not prohibit every molecule that happens to be a peptide. Athletes subject to testing need to check the exact substance and therapeutic-use-exemption rules.
The compounded preparations discussed here are not FDA-approved products. FDA explains that it does not verify a compounded drug’s safety, effectiveness, or quality before marketing (FDA compounding Q&A). A licensed provider may still prescribe a compounded formulation when medically appropriate; that decision belongs to the patient and prescriber.
BPC-157 is a peptide, but not a GH secretagogue
BPC-157 illustrates why “peptide” cannot mean “steroid alternative.” It does not act at the androgen receptor and is not a growth-hormone-releasing peptide. Its published evidence is largely preclinical and does not establish muscle or strength gains in healthy adults. It belongs in a medical discussion only on its own evidence and risks, not by analogy to testosterone or sermorelin.
What a clinical comparison should decide
The first question is the treatment goal and whether human evidence supports a particular compound for it. The next questions are medical history, medications, relevant laboratory markers, fertility plans, glucose regulation, cancer history, and participation in tested sport. A molecular category cannot answer those questions.
At Promise, a licensed provider reviews every request, and not everyone qualifies. The review is where the difference between a plausible mechanism and an appropriate prescription gets tested.